Allogene Overland Biopharm

Allogene Overland Biopharm is a joint venture established in December 2020 by biopharmaceutical company Allogene Therapeutics and Overland Pharmaceuticals. It is dedicated to accelerating the development, manufacturing, and commercialization of Allogene’s CAR-T therapies in the fields of hematologic malignancies and solid tumors in China and other Asia-Pacific regions.